No meaningful difference was found in either injectable or implant birth control when compared to an IUD.
June 13, 2019: Integrated stepped alcohol treatment in HIV clinics; cytokines, inflammation, and heart risk; impact of CCR5 gene editing on lifespan; the costs of "test and treat" for hepatitis C.
Starting July 1, some HIV meds that are widely used will be excluded from their list.
Black men who have sex with men test in high numbers over a lifetime, but not frequently or recently.
The US Preventive Services Task Force released its final ruling in JAMA.
June 6, 2019: HIV/STI risk perceptions differ by race; psychosocial issues and HIV risk among young trans women; switching to dolutegravir/atazanavir; reports of severe hepatotoxicity on dolutegravir.
Advocates say the move is more politics than science.
Rectal and throat tests matter too, and providers should be recommending them.
May 30, 2019: Myocardial infarction risk among people with HIV; dolutegravir vs. efavirenz; a new way to estimate date of seroconversion; identifying people at imminent risk for disengagement from care.
These two tests make it easier to diagnose sexually transmitted infections that often go untreated.